Skip to main content
SpringerLink
Log in

The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer

  • Chapter
  • First Online:
Genitourinary Cancers

Part of the book series: Cancer Treatment and Research ((CTAR,volume 175))

Abstract

Non-muscle-invasive bladder cancer accounts for the majority of incident bladder cancers but is a heterogeneous disease with variation in clinical presentation, course, and outcomes. Risk stratification techniques have attempted to identify those at highest risk of cancer recurrence and progression to help personalize and individualize treatment options. Radical cystectomy during the optimal window of curability could improve cancer outcomes; however, identifying the disease and patient characteristics as well as the correct timing to intervene remains difficult. We review the natural history of non-muscle-invasive bladder cancer, discuss different risk-stratification techniques and how they can help identify those most likely to benefit from radical treatment, and examine the evidence supporting the benefit of timely cystectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O et al (2012) Survival after radical cystectomy of non-bilharzial squamous cell carcinoma versus urothelial carcinoma: a competing-risks analysis. BJU Int 109(4):564–569

    Article  PubMed  Google Scholar 

  2. Aine M, Eriksson P, Liedberg F, Sjödahl G, Höglund M (2015) Biological determinants of bladder cancer gene expression subtypes. Sci Rep 5:10957

    Article  PubMed  PubMed Central  Google Scholar 

  3. Althausen AF, Prout GR, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116(5):575–580

    Article  CAS  PubMed  Google Scholar 

  4. Alvarez-Múgica M, Cebrian V, Fernández-Gómez JM, Fresno F, Escaf S, Sánchez-Carbayo M (2010) Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol 184(4):1507–1513

    Article  PubMed  CAS  Google Scholar 

  5. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151(1):31–35 discussion 35–36

    Article  CAS  PubMed  Google Scholar 

  6. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M (1995) Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 45(1):47–53

    Article  CAS  PubMed  Google Scholar 

  7. Aziz A, Shariat SF, Roghmann F, Brookman-May S, Stief CG, Rink M et al (2016) Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int 117(2):272–279

    Article  PubMed  Google Scholar 

  8. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM (2015) Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Int J Urol 22(2):163–170

    Article  PubMed  Google Scholar 

  9. Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H (2001) The predictive value of muscularis mucosae invasion and p 53 over expression on progression of stage T1 bladder carcinoma. J Urol 165(1):42–46 discussion 46

    Article  CAS  PubMed  Google Scholar 

  10. Bianco FJ, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP (2004) Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22(4):290–294

    Article  PubMed  Google Scholar 

  11. Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, et al (2016) ERBB2 Expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ. Urol Int

    Google Scholar 

  12. Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ et al (2013) Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 44(1):95–102

    Article  PubMed  Google Scholar 

  13. Bruins HM, Skinner EC, Dorin RP, Ahmadi H, Djaladat H, Miranda G et al (2014) Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study. Urol Oncol 32(1):24.e13–24.e19

    Article  Google Scholar 

  14. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC et al (2008) Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54(4):835–843

    Article  PubMed  Google Scholar 

  15. Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169(1):90–95

    Article  PubMed  Google Scholar 

  16. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus calmette-guérin. Eur Urol 69(1):60–69

    Article  PubMed  Google Scholar 

  17. Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S et al (2015) Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol 67(5):876–888

    Article  PubMed  Google Scholar 

  18. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137(2):220–224

    Article  CAS  PubMed  Google Scholar 

  19. Chang SS (2006) The adverse consequences of delaying radical cystectomy. Nat Clin Pract Urol 3(6):300–301

    Article  PubMed  Google Scholar 

  20. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029

    Article  PubMed  Google Scholar 

  21. Chang SS, Cookson MS (2005) Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology 66(5):917–922

    Article  PubMed  Google Scholar 

  22. Chang WC, Chang YH, Pan CC (2012) Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol 36(3):454–461

    Article  PubMed  Google Scholar 

  23. Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS et al (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182(6):2625–2630

    Article  PubMed  Google Scholar 

  24. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152–165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Choong NW, Quevedo JF, Kaur JS (2005) Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 103(6):1172–1178

    Google Scholar 

  26. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA (2003) Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 169(1):101–104

    Article  PubMed  Google Scholar 

  27. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62–67

    Article  CAS  PubMed  Google Scholar 

  28. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE (2007) Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 99(2):281–285

    Article  CAS  PubMed  Google Scholar 

  29. Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56(6):903–910

    Article  PubMed  PubMed Central  Google Scholar 

  30. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111(8):3110–3115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Daneshmand S (2013) Determining the role of cystectomy for high-grade T1 urothelial carcinoma. Urol Clin North Am 40(2):233–247

    Article  PubMed  Google Scholar 

  32. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP et al (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189(5):1656–1661

    Article  PubMed  Google Scholar 

  33. De Berardinis E, Busetto GM, Antonini G, Giovannone R, Gentile V (2011) T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. Int Urol Nephrol 43(4):1047–1057

    Article  PubMed  Google Scholar 

  34. Dell’Oglio P, Tian Z, Leyh-Bannurah SR, Trudeau V, Larcher A, Moschini M et al (2017) Short-form charlson comorbidity index for assessment of perioperative mortality after radical cystectomy. J Natl Compr Canc Netw 15(3):327–333

    Article  PubMed  Google Scholar 

  35. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53(1):146–152

    Article  PubMed  Google Scholar 

  36. Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wiśniewska H et al (2007) Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol 38(5):741–746

    Article  PubMed  Google Scholar 

  37. Droller MJ (2005) Biological considerations in the assessment of urothelial cancer: a retrospective. Urology 66(5 Suppl):66–75

    Article  PubMed  Google Scholar 

  38. Duggan BJ, McKnight JJ, Williamson KE, Loughrey M, O’Rourke D, Hamilton PW et al (2003) The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 9(4):1240–1247

    CAS  PubMed  Google Scholar 

  39. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C et al (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13(12):3545–3551

    Article  PubMed  CAS  Google Scholar 

  40. Faivre d’Arcier B, Celhay O, Safsaf A, Zairi A, Pfister C, Soulié M et al (2010) T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU). Prog Urol 20(6):440–449

    Article  PubMed  Google Scholar 

  41. Farrow GM, Utz DC, Rife CC, Greene LF (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37(8 Pt 2):2794–2798

    CAS  PubMed  Google Scholar 

  42. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195–2203

    Article  PubMed  Google Scholar 

  43. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R et al (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5):992–1001

    Article  PubMed  Google Scholar 

  44. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC et al (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76(5):833–839

    Article  CAS  PubMed  Google Scholar 

  45. Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU et al (2013) Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 182(2):339–349

    Article  CAS  PubMed  Google Scholar 

  46. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57(2):300–309

    Article  PubMed  Google Scholar 

  47. Gakis G, Todenhöfer T, Braun M, Fend F, Stenzl A, Perner S (2015) Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scand J Urol 49(5):382–387

    Article  CAS  PubMed  Google Scholar 

  48. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ et al (1994) Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 73(5):526–532

    Article  CAS  PubMed  Google Scholar 

  49. Goebell PJ, Groshen SG, Schmitz-Dräger BJ (2010) p53 immunohistochemistry in bladder cancer–a new approach to an old question. Urol Oncol 28(4):377–388

    Article  CAS  PubMed  Google Scholar 

  50. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z et al (2013) Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int 111(3):404–411

    Article  PubMed  Google Scholar 

  51. Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D et al (2016) ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69(3):384–388

    Article  CAS  PubMed  Google Scholar 

  52. Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello FJ, Schoenberg MP et al (2009) Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 74(6):1276–1280

    Article  PubMed  Google Scholar 

  53. Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216–1223

    PubMed  Google Scholar 

  54. Hassan JM, Cookson MS, Smith JA, Johnson DL, Chang SS (2004) Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol 172(3):882–884

    Article  PubMed  Google Scholar 

  55. Hautmann RE, Paiss T (1998) Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol 159(6):1845–1850

    Article  CAS  PubMed  Google Scholar 

  56. Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 27(3):347–351

    Article  PubMed  Google Scholar 

  57. Henningsohn L, Steven K, Kallestrup EB, Steineck G (2002) Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 168(1):168–174 discussion 174–165

    Article  PubMed  Google Scholar 

  58. Hermann GG, Horn T, Steven K (1998) The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 159(1):91–94

    Article  CAS  PubMed  Google Scholar 

  59. Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24(22):3664–3671

    Article  PubMed  CAS  Google Scholar 

  60. Herr HW (1983) Carcinoma in situ of the bladder. Semin Urol 1(1):15–22

    CAS  PubMed  Google Scholar 

  61. Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162(1):74–76

    Article  CAS  PubMed  Google Scholar 

  62. Herr HW (2000) Timing of cystectomy for superficial bladder tumors. Urol Oncol 5(4):162–165

    Article  CAS  PubMed  Google Scholar 

  63. Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166(4):1296–1299

    Article  CAS  PubMed  Google Scholar 

  64. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D (2000) Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53(7):676–680

    Article  CAS  PubMed  Google Scholar 

  65. Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D et al (2014) Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association Public Workshop. Urology 83(2):262–264

    Article  PubMed  Google Scholar 

  66. Joudi FN, Smith BJ, O’Donnell MA, Konety BR (2003) Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 62(6):1083–1088

    Article  PubMed  Google Scholar 

  67. Jäger W, Thomas C, Haag S, Hampel C, Salzer A, Thüroff JW et al (2011) Early versus delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int 108(8 Pt 2):E284–E288

    Article  PubMed  Google Scholar 

  68. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P et al (2007) Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62–67

    Article  PubMed  Google Scholar 

  69. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE et al (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881–885

    Article  PubMed  Google Scholar 

  70. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH et al (2012) Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol 61(6):1245–1256

    Article  CAS  PubMed  Google Scholar 

  71. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A et al (2009) Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147–152

    Article  PubMed  Google Scholar 

  72. Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH (2014) Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol 32(8):1191–1199

    Article  PubMed  Google Scholar 

  73. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP et al (2012) Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int 110(8):1163–1168

    Article  PubMed  Google Scholar 

  74. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27(3):361–373

    Article  CAS  PubMed  Google Scholar 

  75. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4(9):e284

    Article  PubMed  PubMed Central  Google Scholar 

  76. Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180(5):1928–1932 discussion 1932

    Article  PubMed  Google Scholar 

  77. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27(2):155–159

    Article  PubMed  Google Scholar 

  78. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6(9):678–686

    Article  CAS  PubMed  Google Scholar 

  79. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247–256

    Article  PubMed  CAS  Google Scholar 

  80. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103(2):117–128

    Article  PubMed  PubMed Central  Google Scholar 

  81. Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J (2015) Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33(6):643–650

    Article  PubMed  Google Scholar 

  82. Masood S, Sriprasad S, Palmer JH, Mufti GR (2004) T1G3 bladder cancer–indications for early cystectomy. Int Urol Nephrol 36(1):41–44

    Article  CAS  PubMed  Google Scholar 

  83. Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF (2016) The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol 13(8):471–479

    Article  CAS  PubMed  Google Scholar 

  84. McConkey DJ, Choi W, Dinney CP (2014) New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 66(4):609–610

    Article  PubMed  Google Scholar 

  85. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP (2015) Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 29(2):377–394 x–xi

    Article  PubMed  Google Scholar 

  86. Miyake M, Gotoh D, Shimada K, Tatsumi Y, Nakai Y, Anai S et al (2015) Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for oncological treatment scoring model: long-term follow-up experience at a single institute. Int J Urol 22(6):541–547

    Article  CAS  PubMed  Google Scholar 

  87. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA (2007) Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 177(1):80–83

    Article  CAS  PubMed  Google Scholar 

  88. Network CGAR (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322

    Article  CAS  Google Scholar 

  89. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS (2006) Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 67(4):737–741

    Article  PubMed  Google Scholar 

  90. Nielsen ME, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY et al (2014) Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988–2006. Cancer 120(1):86–95

    Article  PubMed  Google Scholar 

  91. Olsson H, Hultman P, Rosell J, Jahnson S (2013) Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours. Scand J Urol 47(3):188–195

    Article  PubMed  Google Scholar 

  92. Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Búcar S et al (2005) Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48(2):231–238 discussion 238

    Article  CAS  PubMed  Google Scholar 

  93. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W et al (1991) Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145(1):45–50

    Article  CAS  PubMed  Google Scholar 

  94. Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H (2013) Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol 31(6):849–856

    Article  CAS  PubMed  Google Scholar 

  95. Passoni N, Gayed B, Kapur P, Sagalowsky AI, Shariat SF, Lotan Y (2016) Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol 34(11):485.e487–485.e414

    Article  Google Scholar 

  96. Patriarca C, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M et al (2016) Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagn Pathol 11:6

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S et al (2015) A Molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 68(5):824–832 discussion 835–826

    Article  CAS  PubMed  Google Scholar 

  98. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68(6):959–967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA (2010) Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol 183(3):915–920

    Article  PubMed  Google Scholar 

  100. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562

    Article  CAS  PubMed  Google Scholar 

  101. Prout GR, Griffin PP, Daly JJ (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138(4):766–770

    Article  PubMed  Google Scholar 

  102. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177(4):1283–1286 discussion 1286

    Article  PubMed  Google Scholar 

  103. Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA et al (2015) Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol 67(1):165–170

    Article  PubMed  Google Scholar 

  104. Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E et al (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6(244):244ra291

    Article  CAS  Google Scholar 

  105. Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ (2011) Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 107(1):46–52

    Article  PubMed  Google Scholar 

  106. Riley GF, Potosky AL, Lubitz JD, Kessler LG (1995) Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33(8):828–841

    Article  CAS  PubMed  Google Scholar 

  107. Ro JY, Ayala AG, el-Naggar A (1987) Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 11(9):668–673

    Article  CAS  PubMed  Google Scholar 

  108. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs. T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189(6):2069–2076

    Article  PubMed  Google Scholar 

  109. Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF et al (2014) Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 40(12):1738–1745

    Article  CAS  PubMed  Google Scholar 

  110. Sfakianos JP, Galsky MD (2015) Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice. Urol Clin North Am 42(2):181–187 viii

    Article  PubMed  Google Scholar 

  111. Shah RB, Montgomery JS, Montie JE, Kunju LP (2013) Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 31(8):1650–1655

    Article  PubMed  Google Scholar 

  112. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 25(6):468–475

    Article  CAS  PubMed  Google Scholar 

  113. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177(2):481–487 discussion 487

    Article  PubMed  Google Scholar 

  114. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI et al (2009) Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 182(1):78–84 discussion 84

    Article  PubMed  Google Scholar 

  115. Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y et al (2012) Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 187(2):457–462

    Article  PubMed  Google Scholar 

  116. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF et al (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22(6):1014–1024

    Article  CAS  PubMed  Google Scholar 

  117. Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM et al (2000) Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 56(5):735–740

    Article  CAS  PubMed  Google Scholar 

  118. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K et al (2001) A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88(3):209–216

    Article  CAS  PubMed  Google Scholar 

  119. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93(4):485–490

    Article  CAS  PubMed  Google Scholar 

  120. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

    Article  PubMed  Google Scholar 

  121. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18(12):3377–3386

    Article  PubMed  CAS  Google Scholar 

  122. Soloway MS, Lopez AE, Patel J, Lu Y (1994) Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 73(7):1926–1931

    Article  CAS  PubMed  Google Scholar 

  123. Solsona E, Iborra I, Rubio J, Casanova J, Almenar S (2004) The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 94(9):1258–1262

    Article  PubMed  Google Scholar 

  124. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D et al (2011) Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 108(5):687–692

    PubMed  Google Scholar 

  125. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185(4):1216–1221

    Article  PubMed  Google Scholar 

  126. Sood A, Kachroo N, Abdollah F, Sammon JD, Löppenberg B, Jindal T et al (2017) An evaluation of the timing of surgical complications following radical cystectomy: data from the american college of surgeons national surgical quality improvement program. Urology

    Google Scholar 

  127. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ et al (1998) Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160(3 Pt 1):645–659

    CAS  PubMed  Google Scholar 

  128. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675

    Article  CAS  PubMed  Google Scholar 

  129. Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE et al (2010) Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol 184(4):1296–1300

    Article  CAS  PubMed  Google Scholar 

  130. Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O’Donnell MA et al (2009) The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 103(4):475–479

    Article  PubMed  Google Scholar 

  131. Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R (1987) Radical cystectomy–often too late? Eur Urol 13(6):361–367

    Article  PubMed  Google Scholar 

  132. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S et al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69(2):231–244

    Article  PubMed  Google Scholar 

  133. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970

    Article  CAS  PubMed  Google Scholar 

  134. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465 discussion 475–467

    Article  PubMed  Google Scholar 

  135. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172(1):70–75

    Article  PubMed  Google Scholar 

  136. Thompson IM, Tangen C, Basler J, Crawford ED (2002) Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168(3):1008–1012

    Article  PubMed  Google Scholar 

  137. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G et al (2010) Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 183(5):1757–1763

    Article  PubMed  Google Scholar 

  138. Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP et al (2013) Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int 111(8):1215–1221

    Article  PubMed  Google Scholar 

  139. Tyson MD, Chang SS (2016) Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes. Eur Urol 70(6):995–1003

    Article  PubMed  PubMed Central  Google Scholar 

  140. van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60(3):493–500

    Article  PubMed  Google Scholar 

  141. van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG et al (2014) Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urol Oncol 32(7):1078–1087

    Article  PubMed  CAS  Google Scholar 

  142. van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE et al (2012) Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 110(8):1169–1176

    Article  PubMed  CAS  Google Scholar 

  143. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21(10):1912–1921

    Article  PubMed  CAS  Google Scholar 

  144. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC et al (2010) Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 58(3):433–441

    Article  PubMed  Google Scholar 

  145. Wang J, Wang FW, Lagrange CA, Hemstreet III GP, Kessinger A (2010) Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma

    Google Scholar 

  146. Weizer AZ, Wasco MJ, Wang R, Daignault S, Lee CT, Shah RB (2009) Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 182(1):59–65 discussion 65

    Article  PubMed  Google Scholar 

  147. Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior SW, Thüroff JW (2005) Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95(3):301–305

    Article  PubMed  Google Scholar 

  148. Willis D, Kamat AM (2015) Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am 29(2):237–252 viii

    Article  PubMed  Google Scholar 

  149. Willis DL, Porten SP, Kamat AM (2013) Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 23(5):435–443

    Article  PubMed  Google Scholar 

  150. Xie HY, Zhu Y, Yao XD, Zhang SL, Dai B, Zhang HL et al (2012) Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy. Int Urol Nephrol 44(6):1711–1719

    Article  PubMed  Google Scholar 

  151. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS et al (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer

    Google Scholar 

  152. Yang LS, Shan BL, Shan LL, Chin P, Murray S, Ahmadi N et al (2016) A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol 25(3):281–297

    Article  PubMed  Google Scholar 

  153. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA et al (2007) Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 13(7):2046–2053

    Article  CAS  PubMed  Google Scholar 

  154. Yiou R, Patard JJ, Benhard H, Abbou CC, Chopin DK (2002) Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 89(4):374–378

    Article  CAS  PubMed  Google Scholar 

  155. Younes M, Sussman J, True LD (1990) The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66(3):543–548

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA

    Daniel J. Lee & Sam S. Chang

Authors
  1. Daniel J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sam S. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sam S. Chang .

Editor information

Editors and Affiliations

  1. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

    Siamak Daneshmand

  2. City of Hope National Medical Center, Duarte, CA, USA

    Kevin G. Chan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, D.J., Chang, S.S. (2018). The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. In: Daneshmand, S., Chan, K. (eds) Genitourinary Cancers . Cancer Treatment and Research, vol 175. Springer, Cham. https://doi.org/10.1007/978-3-319-93339-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93339-9_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93338-2

  • Online ISBN: 978-3-319-93339-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation